TRACON Pharmaceuticals, Inc. (TCON) Analysts See $-0.33 EPS on May, 9

April 17, 2018 - By Andrea Pope

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Corporate Logo

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON)’s earnings report is awaited by WallStreet on May, 9, according to RTT. EPS of $-0.33 is 25.00 % up from 2017’s $-0.44 EPS. Analysts at Wall Street see TRACON Pharmaceuticals, Inc.’s -10.81 % EPS growth compared to $-0.37 EPS for last quarter. Lastly it traded at $2.9.Since April 17, 2017 it’s 46.43% down thus downtrending. The stock underperformed the S&P 500 by 57.98%.

TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration , and fibrotic diseases.The firm is worth $51.48 million. The Company’s lead product candidate is TRC105, an endoglin antibody, which is in Phase III clinical trials for angiosarcoma; randomized Phase II clinical trials for renal cell carcinoma; Phase II clinical trials for soft tissue sarcoma; Phase II clinical trials for gestational trophoblastic neoplasia; Phase I/II clinical trials for hepatocellular carcinoma; Phase I clinical trial for lung cancer; Phase I/II clinical trials for breast cancer; and Phase I/II clinical trials for wet AMD.Currently it has negative earnings. The company's other product candidates comprise TRC102, a small molecule that is in Phase II clinical trials for mesothelioma, Phase II clinical trials for glioblastoma, Phase I clinical trial for solid tumors and lymphomas, as well as Phase I clinical trial for lung cancer; and TRC253, a small molecule high affinity competitive inhibitor of wild type androgen receptor (AR) and multiple AR mutant receptors that is in Phase I/II clinical trials for the treatment prostate cancer.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.